ID
45418
Description
Principal Investigator: Benajamin L. Ebert, MD, Brigham and Women's Hospital/Broad Institute MeSH: Hemic and Lymphatic Diseases https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000632 The NHLBI "Grand Opportunity" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the "exome") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO. Two major goals in the study of human malignancies are (i) to understand the genetic basis that underlies the predisposition of certain individuals to develop cancer and (ii) to identify the full spectrum of acquired mutations that occur in human cancers. There has been some progress in both of these areas with respect to hematologic malignancies but much remains to be discovered. As a result of recent advantages in sequencing technologies it is now feasible to sequence multiple individual whole exomes at reasonable cost. Such technologies provide a unique opportunity to transform our understanding of the biological basis of human cancer and to identify inherited genetic variants that predispose individuals to the development of hematologic malignancies. Myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and acute leukemia are clonal disorders of hematopoieis. Our study involves performing whole exome sequencing of individuals with these disorders for the purpose of identifying (i) novel inherited genetic variants associated with the risk of developing of MPN/MDS/acute leukemia and (ii) novel acquired mutations associated with the development of MPN/MDS/acute leukemia. *The ARDSNet iSPAAR Cohort is utilized in the following dbGaP sub-studies.* To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the "Sub-studies" box located on the right hand side of this top-level study page phs000631 ARDSNet iSPAAR Cohort.- phs000334 ESP_LungGO_ALI - phs000new ALI_GeneticRisk
Lien
Mots-clés
Versions (1)
- 11/23/22 11/23/22 - Simon Heim
Détendeur de droits
Benajamin L. Ebert, MD, Brigham and Women's Hospital/Broad Institute
Téléchargé le
November 23, 2022
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000632 NHLBI GO-ESP: Family Studies (Hematological Cancers)
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
- Family ID, subject ID, mother ID, father ID, and sex of participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
- Subject ID, sample ID, and sample use variable obtained from participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
- Subject ID, age, gender, race, primary disease diagnosis, brother ID, sister ID, and son variable of participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
- Sample ID, primary disease diagnosis, biopsy of normal or tumor tissue, primary or metastatic tumor, site of biopsy, and analyte type of samples obtained from participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
- Family ID, subject ID, mother ID, father ID, and sex of participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
- Subject ID, sample ID, and sample use variable obtained from participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
- Subject ID, age, gender, race, primary disease diagnosis, brother ID, sister ID, and son variable of participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
- Sample ID, primary disease diagnosis, biopsy of normal or tumor tissue, primary or metastatic tumor, site of biopsy, and analyte type of samples obtained from participants with or without hematological cancer and involved in the "NHLBI GO-ESP: Family Studies (Hematological Cancers)" project.
C0680251 (UMLS CUI [1,2])
C0023467 (UMLS CUI [1,2])
C0027022 (UMLS CUI [1,3])
C3463824 (UMLS CUI [1,4])
C0679228 (UMLS CUI [1,5])
C0205210 (UMLS CUI [1,6])
C1521733 (UMLS CUI [1,7])
C1521991 (UMLS CUI [1,8])